Disclosures. Advisory Boards 6/10/2014

Size: px
Start display at page:

Download "Disclosures. Advisory Boards 6/10/2014"

Transcription

1 Massachusetts Medical Society 12 th annual Men s Health Symposium 11 June 2014 Testosterone and Cardiovascular Disease Where Does The Real Answer Lie? Andre Guay MD, FACP, FACE, IF (Ret) Director, Center for Sexual Function/Endo Lahey Clinic Northshore, Peabody Clinical Professor of Medicine ( Endocrinology) Tufts University School of Medicine Boston, MA Disclosures Advisory Boards Endo Pharmaceuticals Repros Therapeutics 1

2 Low Testosterone Related To Increased Cardiac Risk And Also To Mortality Low Serum Testosterone and Mortality in Male Veterans N=858 men > age of 40 Low T = total T < 250 ng/ml < 8.7 nmol/l Mortality over 5 years 20.1% with normal T 2 levels > % with equivocal T Equal # N and low Odds Ratio 1.38 (P=0.06) 34.9% with low T 2 levels < 250 Odds Ration 1.88 (P<0.001) Shores et al (Seattle) Arch Int Med 2006; 166:

3 Recent Studies Low Testosterone and Increased Mortality (N >500) HR (95% CI) Nature Men, n Follow- Up, yrs Mortality Shores, ( ) Retrospective All-cause Laughlin, ( ) Prospective CVD Khaw, ( ) Prospective 2314 of 11, All-cause/ CVD Haring, ( ) Prospective All-cause 2.56 ( ) CVD Malkin, ( ) Prospective All-cause in men with CAD Tivesten, ( ) Prospective All-cause Menke, ( ) Prospective All-cause Vikan, ( ) Prospective All-cause Pye ( ) 3.0 if sex sx Prospective All Cause/CVD Jones ( ) Prospective All cause Corona, ( ) Prospective CVD HR=hazard ratio; CI=confidence interval. Risk Factor Prevalence of and Major Risk Factors for Hypogonadism Overall Prevalence of Hypogonadism in Clinical Practice: 38.9% Hypogonadism a Prevalence (95% CI) Odds Ratio (95% CI) Obesity 52.4 ( ) 2.38 ( ) Type 2 diabetes 50.0 ( ) 2.09 ( ) Hypertension 42.4 ( ) 1.84 ( ) Hyperlipidemia 40.4 ( ) 1.47 ( ) Asthma or COPD 43.5 ( ) 1.40 ( ) Prostate disease 41.3 ( ) 1.29 ( ) 6 HIM Study (N = 2085) Adapted from Mulligan T, et al. Int J Clin Pract. 2006;60:

4 Men With Erectile Dysfunction (ED) Have Hypogonadism Due to Varied Chronic Illnesses (N=990) Condition N # Hypo. ( % ) #1 o Hypo ( % ) # 2 o Hypo (% ) Diabetes mellitus (35.6) 12 (5.2) 66 (30.4) Hypertension (34.6) 15 (4.2) 94 (30.4) ASCAD (35.0) 17 (8.6) 52 (26.4) Asthma (45.2) 1 (2.4) 18 (42.8) Seizures (34.4) 3 (5.7) 15 (28.7) OSA (64.3) 2 (4.8) 25 (59.5) Roh (27.1) 7 (5.0) 31 (22.1) Anxiety/Depression (37.0) 17 (8.2) 60 (28.8) Work stress (43.6) 6 (3.0) 80 (40.6) TOTAL (36 %) (6%) (30%) *Lahey Clinic Northshore, Peabody, MA; Case Western Reserve, Cleveland, OH. Guay AT, et al. Int J Imp Res. 2010; 22(3):9-19. Metabolic Syndrome: Defined by the Presence of Any 3 of 5 Components 1. Abnormality of blood sugar/insulin resistance 2. Enlarged waist circumference/bmi (visceral fat) 3. Elevated blood pressure 4. Elevated triglycerides 5. Decreased HDL cholesterol Androgen deficiency/ hypogonadism Obesity Hypertension Dyslipidemia Hyperglycemia Insulin resistance Metabolic syndrome 4

5 Can Testosterone Replacement in Hypogonadism Ameliorate Cardiometabolic Risks? T Therapy Improves Metabolic Syndrome Components FBG HbA1c Fasting insulin HOMA index of insulin resistance Waist circumference, BMI, cholesterol Prevalence of metabolic syndrome (after 1 year) Kapoor D,* et al. Eur J Endocrinol. 2006;154(6): month trial Heufelder AE, et al. J Androl. 2009;30(6): month trial *United Kingdom; Germany, Jones TH, et. al. Diabetes Care. 2011;34:

6 CIMT After 12 Months of Nebido Treatment (n=40) and Correlation Between Change in Testosterone and CIMT. CIMT Correlation of CIMT vs TT P< r 5 = 0.31; P< CIMT=carotid intima media thickness. Aversa A,* et al. J Sex Med. 2010;7(10): Testosterone-Treated Hypogonadal Men Have a Longer Survival Time than Untreated Men* Log Rank p = Treated (n=398) mortality 10.3% 3.4 deaths/100 pat yrs Untreated (n=633) mortality 20.7% 5.7 deaths/100 pat yrs *in 1031 men (mean age ~ 60 years; 38% with type 2 diabetes; 22% with cardiac disease) Shores MM et al. J Clin Endocrinol Metab 97(6): (2012) 6

7 Low Testosterone Predicts Increased Mortality and Testosterone Therapy Improves Survival in 587 Men with Type 2 Diabetes (mean Follow-up: 5.8 years) Low T treated Normal T Low T untreated Mean TRT was for 41.6 months.hr 2.3 for untreated Muraleedharan V et al. Eur J Endo 2013; 169: Recent Meta analyses About Testosterone Therapy Related To Cardiovascular Events 7

8 Meta Analyses For CV Events on T Therapy Calof OM et al. J Gerontology 2005;11: Haddad RM et al. Mayo Clin Proc. 2007;82: Fernández-Balsells NM et al. J. Clin. Endocrinol. Metab. 2010;95:

9 Testosterone Prescription Sales Sales in millions of dollars Year Source: IMS Sales Data, BMC Corp. Courtesy: Reed Selby, ALZA Corporation; Michael Bailey, SmithKline Beecham; Kevin Rose, Solvay-Unimed U.S. annual testosterone sales approaching $1 Billion (Year over year growth in %) % % % Androgel Launch 87% 25% 32% 16% 8% oral (methylated-t) injectable patch/buccal gel total Source: IMS 9

10 Why Have Testosterone Prescriptions Increased? 1. Direct to consumer advertising 2. Subliminal promise of eternal youth 2. Gyms and Athletes Not prescribed but obtained via black market 12 % of high school athletes have taken steroids 3. Anti aging Clinics Run by physicians May recommend testosterone and growth hormone therapy 4. Increased awareness of Hypogonadism (1990 s) 5. Fear of prostate cancer has been answered TOM Trial NEJM

11 In Older Men an Optimal Plasma Testosterone is Associated with Reduced All Cause Mortality and Higher Dihydrotestosterone With Reduced Ischemic Heart Disease Mortality, While Estradiol Levels Do Not Predict Mortality Health in Men Study Perth Australia 4248 men studied at 5 yrs Of men that qualified: N = 2716 remained alive N = 974 died Men who died had an association with low T at baseline No relation of E2 with Mortality Normal T related to increased survival Yeap, et al (Aus) J Clin Endo Metab Epub 20 Nov 2013 doi: /jc Adverse Events Associated With Testosterone Administration: TOM Study Basaria, Bhasin et al (Boston) N.E.J.M. 2010; E-pub 30 June: /NEJMoa TOM = Testosterone in Older Men with Mobility Limitation N = 209 men, > 65 years of age (of the 252 desired by power analysis) Baseline TT ng/dl ( free T < 50 pg/ml or 170 pmol/l ) 1% testosterone gel used, 10 Gm QD, titrated to 5.0 or 15.0, 6 mo rx Aimed for TT between 500 and 1000 ng/dl Results of muscle performance and physical functionwere positive 11

12 Adverse Events Associated With Testosterone Administration: TOM Study More risks in T Rx group Cv disease Hypertension And HTN meds Statin therapy But not statistically significant Basaria, Bhasin et al (Boston) N.E.J.M. 2010; E-pub 30 June: /NEJMoa Adverse Events Associated With Testosterone Administration: TOM Study Placebo Group No major CV event Testosterone Group MI x2 Death, presumed MI x1 CVA x1 Acute coronary syndrome X1 Serious CHF x2 Basaria, Bhasin et al (Boston) N.E.J.M. 2010; E-pub 30 June: /NEJMoa

13 Adverse Events Associated With Testosterone Administration: TOM Study Hazard Ratio of 2.0 for men who had TT levels between 512 ng/dl to 1957 ng/dl At baseline, men with lower TT levels were at greater risk Elevated Hct seems to be a great aggravating factor in men at this age at risk Interesting that BMI, smoking, the presence of DM did not increase risk..but age did Basaria, Bhasin et al (Boston) N.E.J.M. 2010; E-pub 30 June: /NEJMoa Adverse Events Associated With Testosterone Administration: TOM Study Despite all of problems int the design of the paper: Study not powered to find CV events Poor randomization (due to underpowering) T treatment group had patients at higher risk There is a signal for increased CV events: Poor inclusion criteria Class I and II CHF Creatinine levels < 3.5 ng/ml T gel not started at lowest dose before titration Did not aim for midrange T levels Aimed for T levels between ng/dl Reasonable assumption that men had salt and water retention and it resulted in the 7 major CV events Where there were none for the placebo group Basaria, Bhasin et al (Boston) N.E.J.M. 2010; E-pub 30 June: /NEJMoa

14 In Older Men an Optimal Plasma Testosterone is Associated with Reduced All Cause Mortality and Higher Dihydrotestosterone With Reduced Ischemic Heart Disease Mortality, While Estradiol Levels Do Not Predict Mortality Optimal androgen levels are a biomarker for survival because older men with midrange levels of T and DHT had the lowest death rates from any cause Note the trend for increasing mortality with higher T and DHT levels: Especially TT > 30 nmol/l (864ng/dL) Or cft > 500 pmol/l? Explanation for TOM trial results? Yeap, et al (Aus) J Clin Endo Metab Epub 20 Nov 2013 doi: /jc val Do the Effects of Testosterone on Muscle strength, Physical Function, Body Composition, and Quality of Life Persist Six Months After Treatment in Intermediate-Frail and Frail Elderly Men N=274 frail men, ages Treated for 6 months mg/d Total T < 12 nmol/l Calculated free T < 250 pmol/l Total from 11.3 to 18.4 nmol/l Declined to 10.5 nmol/l at 12 months Calc free T went from 175 to 365 pmol/l Declined to 172 pmol/l at 12 months Need to continnue Rx NO ADVERSE CV EVENTS O Connell, Srinivas-Shankar, Wu et al (UK) J.C.E.M. 2011; 96:

15 Effect of Long-Acting Testosterone treatment on Functional Exercise Capacity, Skeletal Muscle Performance, Insulin Resistance, and Baroreflex Sensitivity in Elderly Patients With Chronic Heart Failure N=70 elderly men with stable CHF, median age 70 years Peak O2 (VO2) increased with T rx, as did muscle strength, 6MWT MVC (max vol muscle contraction) increased on T Rx EF increased but not significantly Caminiti, Rosano et al (It) J Am Coll Card 20019; 54: Cardiorespiratory and Muscular Results before and after 3 mo of Treatment with Nebido in 64 Frail Elderly Men with Chronic Heart Failure * * * * * *p<0.05 Caminiti G et al. J Am Coll Cardiol 54: (2009) 15

16 Metabolic and Hormonal Results before and after 3 mo of Treatment with Nebido in 64 Frail Elderly Men with Chronic Heart Failure * *p<0.05 * 6- Minute Walking Test (m) * Caminiti G et al. J Am Coll Cardiol 54: (2009) Xu et al Biomedical Central On-Line Journal

17 Testosterone Therapy and Cardiovascular Events Among Men: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Trials 1,882 papers obtained; 27 used Table 1: men who had low T and/or chronic disease Search Terms: tetosterone, androgen, random, trial 12 had TT < 10.4 nmol/l Or 300 ng/dl 12 had TT > 10.4 nmol/l No Rx T levels available No correlation of CV events with any T levels Xu L, et al BMC Medicine 2013, 11:108 Testosterone Therapy and Cardiovascular Events Among Men: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Trials o Conclusion? Biased,?Relevant: o The effects of testosterone on cardiovascular-related events varied with source of funding o Fig 4 o Upper panel sponsored by Pharma o o 3 studies had inadequate levels Lower panel, no Pharma support o 4 studies had inadequate levels o Eliminate Basaria 2010 o Would have changed the OR o If a number of men had T, then one can make the case for low T related to CV events Xu L, et al BMC Medicine 2013, 11:108 17

18 Vigen et al JAMA November 2013 Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels Study Population: at risk population of veterans who underwent coronary arteriography N = 8709 men with TT < 300ng/dL (<10.4 nmol/l) Of 7486 men NOT RECEIVING T Rx: 681 died, 420 had MI, 486 had CVA Incidence of AE: 21.2% Of 1223 men RECEIVING T Rx:d 67 dies, 23 had MI, 33 had CVA Incidence of AE: 10.0% Vigen, et al (VA Study in USA) J.A.M.A. 2013; 310:

19 Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels Since population biased for CAD How to generalize this data to apply to a general population? Applied the stabilized inverse probability of treatment weighting There are no standardized method of assigning statistical weights Subjective definitions by each study group Over 50 variables were weighted, but it was not clear if there was any adjustment for multiple risk factors, or whether and how the authors took into consideration to correlations between the factors N=1132 men excluded from the study Not available for the T risk Group Should have been added to the NON T Group Could have made a separate arm Vigen, et al (VA Study in USA) J.A.M.A. 2013; 310: JAMA Abstracts Before and after Revision The absolute rate of events were 19.9% in the no testosterone group vs 25.7% in the testosterone therapy group, with an absolute risk difference of 5.8% at 3 years after coronary arteriography At 3 years after coronary arteriography, the Kaplan-Meier estimated cumulative percentages with events were 19.9% in the no testosterone therapy group vs 25.7% in the testosterone therapy group, with an absolute risk difference of 5.8% 19

20 Diagnosis and Treatment of Hypogonadism Diagnosis of Hypogonadism Total T < 300 ng/dl (10.4 nmol/l) has been the standard in the past The definition of testosterone deficiency involves a biochemical number plus consistent signs and symptoms of androgen deficiency Bhasin S, et al. J Clin Endocrinol Metab 2010; 95: There is no mention in the JAMA report of any symptomotology No mention of any confirmatory blood test being done Up to 30% of low TT has been shown to be normal on retesting Brambilla DJ, et al. Clin Endocrinol (Oxf) 2007; 67: No mention of the time of day the test was done Even many repeat TT in Am in older men were found to be normal Brambilla DJ, et al. Clin Endocrinol (Oxf) 2007; 67: Only 60% of the men had post rx Testosterone levels The 40% with no tests should have been eliminated from the study Vigen, et al (VA Study in USA) J.A.M.A. 2013; 310: Diagnosis and Treatment of Hypogonadism Treatment of Testosterone Deficiency.? Inadequate 63.9% of the men were given the low, 2.5 mg, Testosterone patch The VA requires that T treatment is begun with patches Most clinicians would start at 5.0 mg Also, nearly half of the men develop dermatitis The mean number of refills was 6 So, 80% of the men were treated for about 6 months The mean treatment T level was 332 ng/dl (11.5 nmol?l) and levels of T on treatment was only carried out in 60% of the men Many feel that the cutoff for testosterone deficiency should be a TT < 350 ng/dl (12.1 nmol/l) Wang C, et al. J Androl 2009 doi: /jandrol Maggi M, et al. J Sex Med 2013; 10: Bhasin S,et al. J Clin Endocrinol Metab 2011; 95: Vigen, et al (VA Study in USA) J.A.M.A. 2013; 310:

21 Finkle et al PLOS one On line Journal January 2014 Increased Risk of Non Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men Cohort Formation 1 st Prescription for Testosterone.N = 55,593 (48,539 men < 65) Comparison population 1 st Prescription for PDE5.N = 167,279 Post Prescription F/U 90 days..then from days because many men dropped out in the first 90 days Pre Prescription..25 months!!!!...how cam you compare 90 days and 25 months? Why PDE5 as comparison group because some indications for prescription are similar to those for T Transcription.WRONG!!! Only indication for PDE5 is ED, and ED not an indication for TT because PDE5 s not associated with cardiovascular events Makes populations quite different.. Men with multiple medical co factors may not be eligible to receive a PDE5 Finkle WD, et al PLOS/one Jan 2014/ V9/ Issue 1/ e

22 Increased Risk of Non Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men PDE5 patients were weighted to match the TT cohort on odds of testosterone prescription.. So a guess 141,031./. 167,279 = 84% chance of needing a prescription Without weighting there are more men with hyperlipidemia, hypertension, heart disease, asthma, SSRI s, Corticosteroids, insulin and anti-diabetic drugs in the T Rx group Putting the odds at 84% evens the groups out wonderfully well Finkle WD, et al PLOS/one Jan 2014/ V9/ Issue 1/ e Increased Risk of Non Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men So what is the true prevalence of hypogonadism in ED? 1. Kohler. Prevalence of And Def in ED. Urology 2008 Prevalence of 23% (TT < 300ng/dL) 2. Somani. Screening for MS and T Def in ED. BJU Int 2010 Prevalence of 27% ( with cft < 220 pmol/l) 3. Guay. Characterization of men in an endocrine clinic. Endo Prac 1999 Prevalence of 36% (TT < 300 ng/dl) 4. Wu. Identification of LOH in Eur Male Aging Study. N.E.J.M Prevalence of 33% (with cft < 220 pmol/l) 5. Isidori. Critical analysis of Testosterone on erectile function. Eur Urol 2013 Prevalence between 23% and 36% Why bother to worry about the prevalence? There is no mention of T levels, before or after a rx for testosterone There is no assurance that the men ever took the medication Finkle WD, et al PLOS/one Jan 2014/ V9/ Issue 1/ e

23 Take Home Messages I would not recommend stopping testosterone therapy o the basis of the recent publicized studies There is overwhelming evidence that the opposite is true, i.e., cardiovascular risk is related to low testosterone Androgen Study Group 23

Testosterone Therapy in Men An update

Testosterone Therapy in Men An update Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None

More information

Erectile Dysfunction, Cardiovascular Risk and

Erectile Dysfunction, Cardiovascular Risk and Erectile Dysfunction, Cardiovascular Risk and Testosterone National Lipid Association (NLA) 2016 Fall Clinical Update August 26-28, 2016 Amelia Island, Fl Robert A. Kloner MD, PhD Director of the Cardiovascular

More information

The reality of LOH-symptoms

The reality of LOH-symptoms The reality of LOH-symptoms PRISM IV Bruges, Belgium September 25-26, 2014 Dr. Herman Leliefeld Androsmannenkliniek The Netherlands The reality of LOH symptoms male external & internal genitalia Testosterone

More information

Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None

Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone

More information

NEW DEVELOPMENTS: T & CVD FDA & THE T TRIALS

NEW DEVELOPMENTS: T & CVD FDA & THE T TRIALS NEW DEVELOPMENTS: T & CVD FDA & THE T TRIALS 2017 UPDATE FDUS Martin Miner MD Clinical Professor of Family Medicine and Urology Co-Director The Men s Health Center The Miriam Hospital Warren Albert School

More information

Disclosures. Faculty 3/5/18. Testosterone, the FDA and CVD Risk Controversies. Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI

Disclosures. Faculty 3/5/18. Testosterone, the FDA and CVD Risk Controversies. Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI Testosterone, the FDA and CVD Risk Controversies Faculty Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI 2 Disclosures Matt Rosenberg, MD serves on the advisory board for Bayer,

More information

Update on diagnosis and complications of adult and elderly male hypogonadism

Update on diagnosis and complications of adult and elderly male hypogonadism Hypoandrogenism in the elderly: to treat or not to treat? 12 th Italian AME Meeting; 6 th joint Meeting with AAC Bari november 10th Update on diagnosis and complications of adult and elderly male hypogonadism

More information

An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health

An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY

More information

TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER?

TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY (TRT) Nuno Tomada, MD, PhD Department of Urology of Hospital S. João Faculty of

More information

Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA

Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prevailing context Increase number of men who are potential candidates for Testosterone Replacement Therapy

More information

Estrogens vs Testosterone for cardiovascular health and longevity

Estrogens vs Testosterone for cardiovascular health and longevity Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in

More information

Point-Counterpoint: Late Onset Hypogonadism (LOH)

Point-Counterpoint: Late Onset Hypogonadism (LOH) Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx

More information

Take-Home Messages: Androgens

Take-Home Messages: Androgens Take-Home Messages: Androgens Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery University of Ottawa SUMMARY SLAMS Symposium Clinical

More information

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research

More information

Testosterone and PDE5 inhibitors in the aging male

Testosterone and PDE5 inhibitors in the aging male Testosterone and PDE5 inhibitors in the aging male Francesco Romanelli Department of Experimental Medicine Medical Pathophysiology, Food Science and Endocrinology Section Sapienza University of Rome 3005

More information

HORMONE THERAPY IN AGING MALE ATHLETES

HORMONE THERAPY IN AGING MALE ATHLETES DISCLOSURES HORMONE THERAPY IN AGING MALE ATHLETES No relevant affiliations or financial interests When, Why and is it Safe? OBJECTIVES Summarize the benefits of optimizing hormone balance Examine the

More information

Outline. Classic Androgen deficiency. Cardiovascular Risk and Testosterone Fact vs Fiction. Professor Robert I McLachlan AM, FRACP, PhD

Outline. Classic Androgen deficiency. Cardiovascular Risk and Testosterone Fact vs Fiction. Professor Robert I McLachlan AM, FRACP, PhD Health Ed Brisbane Saturday 27 th October 2018 Cardiovascular Risk and Testosterone Fact vs Fiction Professor Robert I McLachlan AM, FRACP, PhD Hudson Institute of Medical Research, Monash University Department

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

HHS Public Access Author manuscript Int J Impot Res. Author manuscript; available in PMC 2015 September 01.

HHS Public Access Author manuscript Int J Impot Res. Author manuscript; available in PMC 2015 September 01. Testosterone Therapy and Mortality Risk Michael L. Eisenberg, MD 1, Shufeng Li, MS 2, Danielle Herder, MD 3, Dolores J. Lamb, PhD 4, and Larry I. Lipshultz, MD 4 1 Assistant Professor, Departments of Urology

More information

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic

More information

Hormone Replacement Therapy

Hormone Replacement Therapy Hormone Replacement Therapy What Role Should It Play With Our Patients? Noel R. Williams MD, FACOG TESTOSTERONE FOR MEN: SALVATION OR SNAKE OIL? Definition Male hypogonadism means the testicles don't produce

More information

A dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male

A dro r gen e R e R p e lac a e c m e e m n e t t T her e a r p a y Androgen Replacement Therapy in the Aging O j b ecti t ve v s Male Androgen Replacement Therapy in the Aging Male Thomas J. Walsh, MD, MS Department of Urology University of California, San Francisco Objectives 1. List 3 effects of androgens on normal male physiology.

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial Michelle L. O Donoghue, Robert P. Giugliano, Anthony C. Keech, Estella Kanevsky, KyungAh Im, Peter S. Sever, Terje

More information

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD. Achieving Harmony in Blood Pressure Guidelines Around the Globe Roger S. Blumenthal, MD The Kenneth Jay Pollin Professor of Cardiology Director, The Johns Hopkins Ciccarone Center for the Prevention Of

More information

Sleep Apnea: Vascular and Metabolic Complications

Sleep Apnea: Vascular and Metabolic Complications Sleep Apnea: Vascular and Metabolic Complications Vahid Mohsenin, M.D. Professor of Medicine Yale University School of Medicine Director, Yale Center for Sleep Medicine Definitions Apnea: Cessation of

More information

Hypogonadism* (män) Erytrocytos Kardiovaskulär risk

Hypogonadism* (män) Erytrocytos Kardiovaskulär risk Hypogonadism* (män) Erytrocytos Kardiovaskulär risk *Lågt Testosteron och symtom Stefan Arver ANOVA, Karolinska Univ Sjukhuset Inst. F Medicin/Huddinge Karolinska Institutet Endokrindagar i Umeå 2019 1

More information

CLINICAL OUTCOME Vs SURROGATE MARKER

CLINICAL OUTCOME Vs SURROGATE MARKER CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical

More information

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor

More information

Low T? Late Onset Hypogonadism

Low T? Late Onset Hypogonadism University of Vermont ScholarWorks @ UVM Family Medicine Clerkship Student Projects College of Medicine 2014 Low T? Late Onset Hypogonadism Cheng-Wei Huang University of Vermont Follow this and additional

More information

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence

More information

EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE

EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE Matthew Ho, PGY-2 Department of Urologic Sciences University of British Columbia OBJECTIVES 1. Review the characteristics

More information

The Metabolic Syndrome: Is It A Valid Concept? YES

The Metabolic Syndrome: Is It A Valid Concept? YES The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

More information

PRISM Bruges June Herman Leliefeld Urologist. The Netherlands

PRISM Bruges June Herman Leliefeld Urologist. The Netherlands PRISM Bruges 25-26 June 2015 Herman Leliefeld Urologist The Netherlands Guidelines EAU 2015: a rich source of Knowledge! Epidemiology/ Aetiology / Pathology Diagnostic evaluation Disease management Follow-Up

More information

Testosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd.

Testosterone Replacement Therapy for Hypogonadism: Learning Objectives. What Is the Evidence? Is It Safe? Case Study. Case Study contd. 4 4:4pm Testosterone Therapy: Examining the Evidence SPEAKER Culley Carson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Culley Carson, MD: Consultant

More information

How to treat: TRT modalities and formulations

How to treat: TRT modalities and formulations How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

New Paradigms in Predicting CVD Risk

New Paradigms in Predicting CVD Risk New Paradigms in Predicting CVD Risk Imaging as an Integrator of Lifetime Risk Exposure Michael J. Blaha MD MPH Presented by: Michael J. Blaha September 24, 2014 1 Talk Outline Risk factors vs. Disease

More information

What Is the Low T Syndrome? Is Testosterone Supplementation Safe?

What Is the Low T Syndrome? Is Testosterone Supplementation Safe? What Is the Low T Syndrome? Is Testosterone Supplementation Safe? UCSF Osher Mini Medical School March 7, 2018 Dolores Shoback, MD Staff Physician SF-VAMC Professor of Medicine, UCSF No disclosures or

More information

9/2/2016. Faculty. Learning Objectives. Disclosures. Prevalence of Hypogonadism. Prevalence of HG (cont)

9/2/2016. Faculty. Learning Objectives. Disclosures. Prevalence of Hypogonadism. Prevalence of HG (cont) Faculty Testosterone Replacement Therapies: Mitigating Cardiometabolic Risks Associated with Hypogonadism Pamela Ellsworth, MD Professor of Urology University of Massachusetts Medical School Vice Chair,

More information

Dyslipidemia in women: Who should be treated and how?

Dyslipidemia in women: Who should be treated and how? Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European

More information

Does TRT Induce Prostate Cancer?

Does TRT Induce Prostate Cancer? Does TRT Induce Prostate Cancer? Prism VI, Bruges, Belgium 21-22November 2014 Herman Leliefeld, Urologist, Utrecht The Netherlands Does TRT Induce Prostate Cancer? Why is it a controversial topic? Is there

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

Options for Treatment of Hypogonadism in Men Desiring Fertility Preservation

Options for Treatment of Hypogonadism in Men Desiring Fertility Preservation Options for Treatment of Hypogonadism in Men Desiring Fertility Preservation Natan Bar-Chama MD Director Male Reproductive Medicine and Surgery The Mount Sinai School of Medicine New York NY American Association

More information

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health

More information

Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction

Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction N.Skliros, N.Ioakeimidis, D.Terentes-Printzios, C.Vlachopoulos Cardiovascular Diseases and Sexual Health

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Diabetes and the Heart

Diabetes and the Heart Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with

More information

FLAWED TESTOSTERONE ANALYSIS SPURS MISLEADING MEDIA HEADLINES

FLAWED TESTOSTERONE ANALYSIS SPURS MISLEADING MEDIA HEADLINES http://www.lef.org/ FLAWED TESTOSTERONE ANALYSIS SPURS MISLEADING MEDIA HEADLINES By Blake Gossard, Kira Schmid, ND, Luke Huber, ND, MBA, Steven V. Joyal, MD The precipitous decline of men's testosterone

More information

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine

More information

Men Getting Older Will Testosterone Keep Him Young?

Men Getting Older Will Testosterone Keep Him Young? Men Getting Older Will Testosterone Keep Him Young? Alvin M. Matsumoto, M.D. Associate Director, GRECC V.A. Puget Sound Health Care System Professor, Department of Medicine Division of Gerontology and

More information

Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome

Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

ENDOCRINOLOGICAL IMPLICATIONS AND COMPLICATIONS OF TESTOSTERONE REPLACEMENT IN AGEING MEN

ENDOCRINOLOGICAL IMPLICATIONS AND COMPLICATIONS OF TESTOSTERONE REPLACEMENT IN AGEING MEN ENDOCRINOLOGICAL IMPLICATIONS AND COMPLICATIONS OF TESTOSTERONE REPLACEMENT IN AGEING MEN Frederick C.W. Wu Professor of Medicine and Endocrinology Andrology Research Unit, Centre for Endocrinology and

More information

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System

More information

Testosterone therapy in the new era of Food and Drug Administration oversight

Testosterone therapy in the new era of Food and Drug Administration oversight Review Article Testosterone therapy in the new era of Food and Drug Administration oversight Bethany Desroches 1, Taylor P. Kohn 2, Charles Welliver 3, Alexander W. Pastuszak 1,4 1 Scott Department of

More information

Testosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands

Testosterone Therapy and the Prostate. Frans M.J. Debruyne Professor of Urology The Netherlands Testosterone Therapy and the Prostate Frans M.J. Debruyne Professor of Urology The Netherlands TRT- Risks Prostate ( Cancer, BPH )? Cardiac? Lipids? Polycythemia Sleep apnea Gynecomastia Edema Testosterone

More information

Cedars Sinai Diabetes. Michael A. Weber

Cedars Sinai Diabetes. Michael A. Weber Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor

More information

CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME

CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME Enrico Carmina Executive Director & CEO of Androgen Excess & PCOS Society Professor of Endocrinology Department of Health Sciences and Mother and Child

More information

Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency

Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency

More information

Present and future association between obesity and hypogonadism in Italian male

Present and future association between obesity and hypogonadism in Italian male ORIGINAL PAPER DOI: 10.4081/aiua.2014.1.26 Present and future association between obesity and hypogonadism in Italian male Valentina Boddi 1, Valeria Barbaro 2, Paul Mc Nieven 3, Mario Maggi 1, Carlo Maria

More information

Vitamin D: Conflict of Interest Statement Corporate. Outline 7/5/2016

Vitamin D: Conflict of Interest Statement Corporate. Outline 7/5/2016 Vitamin D: What s New and Not? Clifford J Rosen MD Maine Medical Center Research Institute rosenc@mmc.org Conflict of Interest Statement Corporate NO STOCKS or EQUITY Editor UpToDate, New England Journal

More information

Correlation of novel cardiac marker

Correlation of novel cardiac marker Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely

More information

HYPERTENSION: UPDATE 2018

HYPERTENSION: UPDATE 2018 HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million

More information

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS? HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL

More information

ADT AND CARDIOVASCULAR RISK: should Antagonists be the primary choice for ADT?

ADT AND CARDIOVASCULAR RISK: should Antagonists be the primary choice for ADT? ADT AND CARDIOVASCULAR RISK: should Antagonists be the primary choice for ADT? Igor Tsaur University Medicine Mainz COI Urologische Klinik und Poliklinik Off-label use of drugs, devices, or other agents:

More information

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were

More information

Tesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies

Tesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies Tesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies Copyright 2016. All Rights Reserved. Property of Theratechnologies Inc. Mechanism of Action of Tesamorelin

More information

HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY)

HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) HYPOGONADISM DEFINITION: PRODUCTION OF SEX HORMONES AND GERM CELLS IS INADEQUATE (ENDOCRINE SOCIETY) DEFECT OF THE REPRODUCTIVE SYSTEM THAT RESULTS IN LACK OF FUNCTION OF THE GONADS (Wikipedia) REDUCTION

More information

Update in Hypertension

Update in Hypertension Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded

More information

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories

More information

PCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS

PCa Commentary. Prostate Cancer? Where's the Meat? - A Collection of Studies Supporting the Safety of Its Use. Seattle Prostate Institute CONTENTS Volume 70 July - August 2011 PCa Commentary SEATTLE PROSTATE INSTITUTE CONTENTS TESTOSTERONE REPLACEMENT in Hypogonadal Men with Treated and Untreated Prostate Cancer? 1 TESTOSTERONE REPLACEMENT in Hypogonadal

More information

Hypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated.

Hypogonadism 4/27/2018. Male Hypogonadism -- Definition. Epidemiology. Objectives HYPOGONADISM. Men with Hypogonadism. 95% untreated. Male Hypogonadism -- Definition - Low T, Low Testosterone Hypogonadism -...a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone due to pathology

More information

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,

More information

The target blood pressure in patients with diabetes is <130 mm Hg

The target blood pressure in patients with diabetes is <130 mm Hg Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is

More information

Can men on AS be treated with testosterone?

Can men on AS be treated with testosterone? Can men on AS be treated with testosterone? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Conflicts of interest PI or member steering

More information

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered

More information

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t? Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION

MANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals

More information

Update in the Literature 2012

Update in the Literature 2012 Update in the Literature 2012 Mel L. Anderson, MD, FACP Chief, Hospital Medicine Section Associate Chief, Medical Service Denver VA Medical Center Associate Professor of Medicine University of Colorado

More information

SESSION 3 11 AM 12:30 PM

SESSION 3 11 AM 12:30 PM SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Management of Cardiovascular Disease in Diabetes

Management of Cardiovascular Disease in Diabetes Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western

More information

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator

More information

Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes

Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Diagnosis and Clinical Evaluation of Hypogonadism in Adult Patients with Obesity and Diabetes Adrian Dobs, M.D., M.H.S. Professor of Medicine and Oncology The Johns Hopkins University School of Medicine

More information

The Burden of the Diabetic Heart

The Burden of the Diabetic Heart The Burden of the Diabetic Heart Dr. Ghaida Kaddaha (MBBS, MRCP-UK, FRCP-london) Diabetes Unit Rashid Hospital Dubai U.A.E Risk of CVD in Diabetes Morbidity and mortality from CVD is 2-4 fold higher than

More information

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Basaria S, Harman SM, Travison TG, et al. The effects of testosterone administration for three years on subclinical atherosclerosis progression in older men with low or low

More information

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease

Clinical and Economic Value of Rivaroxaban in Coronary Artery Disease CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban

More information

Decline in CV-Mortality

Decline in CV-Mortality Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer

More information

Vitamin D and Calcium Therapy: how much is enough

Vitamin D and Calcium Therapy: how much is enough Vitamin D and Calcium Therapy: how much is enough Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco DISCLOSURE Nothing to disclose 1 RECOMMENDATIONS

More information

The Endocrine Society Guidelines

The Endocrine Society Guidelines Vitamin D and Calcium Therapy: how much is enough DISCLOSURE Daniel D Bikle, MD, PhD Professor of Medicine VA Medical Center and University of California San Francisco Nothing to disclose RECOMMENDATIONS

More information

Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany

Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany The demographic issue Life expectancy is increasing Patients are getting

More information

Managing Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University

Managing Testosterone Deficiency: A Practical Guide. John Grantmyre MD Professor of Urology Dalhousie University Managing Testosterone Deficiency: A Practical Guide John Grantmyre MD Professor of Urology Dalhousie University 1 2 Case Study #1 A 59-Year-Old Man with Erectile Dysfunction 3 Case History Robert is a

More information

TRT and localized protate cancer

TRT and localized protate cancer TRT and localized protate cancer Frans M. J. Debruyne Professor of Urology PRISM BRUGES Increased risk of prostate cancer with TRT? Prostate cancer Testosterone and Prostate Cancer There appears to be

More information

Modifiable Up-Stream Risk Factors:

Modifiable Up-Stream Risk Factors: Modifiable Up-Stream Risk Factors: Recent Studies in AF Prevention Behzad Pavri, MD, FACC, FHRS Professor of Medicine Director, CCEP Fellowship Thomas Jefferson University Hospital, Philadelphia, USA Disclosures

More information

Primary Care Updates ACP conference 2015

Primary Care Updates ACP conference 2015 Primary Care Updates ACP conference 2015 Richard Rose, MD FACP Assistant Professor University of Utah Department of General Internal Medicine VAMC - Internal Medicine Nothing to disclose Conflicts of interest

More information